Dollvet
From its establishment in 2002 to the present, Dollvet has sensitively focused on importance of technical infrastructure, equipment, large staff and human resources. As of 2019, more than half of over 150 employees consists of experts that highly qualified technical staff. With its contemporary infrastructure, extensive expert staff and experience, Dollvet produces ultimate vaccines at domestic and international level against outbreak disease that endangers livestock economies of countries. Biotechnological product investments have a strategic importance for all of independent world countries. These product investments have a strategical importance for all of independent world countries. These products play an important role in services of fighting against outbreak diseases that affect national economies deeply and constitute extreme dangers for human and animal health.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Livestock
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2002
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
- Ultradoll - Model 8 - Bacterin Toxoid Vaccine
- Tetrandoll - Combined Enterotoxemia Infectious Necrotic Hepatitis and Blackleg Disease Vaccine
- Mastidoll - Model 3 - Inactivated Vaccine for Protection Against Subclinical and Clinical Mastitis
- Orfdoll - Live Ecthyma Vaccine
- Brudoll - Model A Genç - Female Cattle Injectable Suspension Lyophilizate Vaccine